CYTK Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 2% planned / 98% discretionary
Largest single sale: $6.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO | Sell | 7,500 | $65.46 | $491.0K | 278,544 −2.6% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $68.29 | $239.0K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 97,926 | $69.33 | $6.8M | None left | |
| Landry Robert E | Director | Sell | 1,000 | $72.13 | $72.1K | 8,184 −10.9% of holding | |
| Blum Robert I | President & CEO | Sell 10b5-1 | 7,500 | $73.44 | $550.8K | 377,820 −1.9% of holding | |
| Landry Robert E | Director | Sell | 1,000 | $74.66 | $74.7K | 9,184 −9.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.46 | $264.1K | 153,902 −2.2% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $71.48 | $357.4K | 10,784 −31.7% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 10,000 | $70.24 | $702.4K | 58,555 −14.6% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.24 | $526.8K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.82 | $265.4K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $76.76 | $575.7K | 377,820 −1.9% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | $79.88 | $1.1M | 58,555 −19.3% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $80.87 | $606.5K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $80.59 | $282.1K | 153,902 −2.2% of holding | |
| Blum Robert I 2 fills | President & CEO | Sell | 7,500 | $82.02 | $615.2K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $86.62 | $303.2K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $85.80 | $1.3M | 58,555 −20.4% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $84.92 | $636.9K | 377,830 −1.9% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 1,112 | $87.79 | $97.6K | 63,221 −1.7% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 3,134 | $85.00 | $266.4K | 63,221 −4.7% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 38,730 | $82.30 | $3.2M | 63,221 −38% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $79.51 | $278.3K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.46 | $528.5K | 385,330 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $67.98 | $237.9K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1.1M | 58,555 −20.4% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $74.08 | $370.4K | 15,784 −24.1% of holding | |
| Kaye Edward M. MD | Director | Sell | 2,933 | $76.09 | $223.2K | 10,283 −22.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $77.21 | $579.1K | 392,830 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.69 | $264.9K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $77.92 | $584.4K | 400,330 −1.8% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | $1.8M | 63,221 −27.4% of holding | |
| HENDERSON JOHN T | Director | Sell | 20,000 | $75.97 | $1.5M | 75,237 −21% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 11,333 | $77.25 | $875.5K | 58,555 −16.2% of holding | |
| WIERENGA WENDELL | Director | Sell | 4,032 | $75.00 | $302.4K | 32,637 −11% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $77.37 | $270.8K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | $1.0M | 58,555 −21.3% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $63.26 | $948.9K | 58,555 −20.4% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $59.62 | $447.2K | 407,830 −1.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $65.69 | $229.9K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 7,449 | $66.02 | $491.8K | 58,555 −11.3% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $65.38 | $490.4K | 415,330 −1.8% of holding | |
| Malik Fady Ibraham 2 fills | EVP Research & Development | Sell | 4,500 | $65.11 | $293.0K | 153,902 −2.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.